Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CD-41 calf1 calf2 ITGA-2B ITGB-3 CD-61 ITGA-2B ?-IIb ?-2b GP-IIb GP-2b alpha ?IIb?-3 ?
- Product Overview:
CD41, also known as integrin ?2b (ITGA2B), is a protein subunit of the heterodimeric integrin ?IIb?3 complex.{65453} It is composed of N-terminal extracellular ?-propeller, thigh, calf-1, and calf-2 domains, a transmembrane domain, and a C-terminal cytoplasmic domain.{65454} CD41 is expressed in platelets, as well as fetal hematopoietic stem and progenitor cells and a subtype of aging adult hematopoietic stem cells.{65455,65453} Signaling through the ?IIb?3 complex occurs via inside-out or outside-in mechanisms. Inside-out signaling occurs when a ligand binds and increases the affinity and avidity of the complex for ligands containing the Arg-Gly-Asp integrin recognition sequence, such as fibrinogen and von Willebrand factor, that are required for platelet aggregation and adhesion.{65455} Outside-in signaling of the ?IIb?3 complex regulates platelet spreading and plug formation and occurs due to integrin clustering or ligation and integration signaling from additional plasma membrane receptors. Various mutations in ITGA2B or ITGB3, the gene encoding CD61, the ?IIb?3 complex ?3 subunit, lead to a loss of ?IIb?3 expression and are associated with Glanzmann thrombasthenia, a coagulation disorder characterized by impaired clotting, abnormal bleeding, and bruising.{65454,65456} Cayman’s ITGA2B/CD41 Chimeric Monoclonal Antibody was produced recombinantly from the original 7E3 Fab antibody sequence and can be used for flow cytometry (FC). The 7E3 antibody was generated by immunization of mice with washed platelets, followed by fusion of the mouse spleen cells with a mouse myeloma cell line and subcloning.{65457,65458,65459}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.